The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
 
Alison R. Sehgal
Research Funding - Juno Therapeutics; Kite/Gilead; Merck
 
Gerhard Hildebrandt
Stock and Other Ownership Interests - Abbvie; Aetna; Aimmune; ANGI Homeservices; Axim Biotechnologies; Bayer; Bayer; Bluebird Bio; Bristol-Myers Squibb/Medarex; Cardinal Health; CareTrust Reit; Celgene; Cellectis; Charlotte's Web; Clovis Oncology; crispr therapeutics; CVS Health; Endocyte; GW Pharmaceuticals; IDEXX Laboratories; Immunomedics; Insys Therapeutics; Johnson & Johnson; Juno Therapeutics; Kite, a Gilead company; Medical Properties Trust; Novartis; Pfizer; Procter & Gamble; Sangamo Bioscience; Scotts Miracle-Gro; Vertex
Consulting or Advisory Role - Incyte; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Kite, a Gilead company; Pfizer
Research Funding - Jazz Pharmaceuticals; Pharmacyclics; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Falk Foundation; Incyte; Incyte; Jazz Pharmaceuticals; Kite, a Gilead company; Pfizer
 
Nilanjan Ghosh
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen Oncology; Kite/Gilead; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
John E. Godwin
Speakers' Bureau - Abbvie; Bristol-Myers Squibb
 
Nina D. Wagner-Johnston
Consulting or Advisory Role - ADC Therapeutics; Bayer; Calibr; Gilead Sciences; Regeneron; Verastem
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Astex Pharmaceuticals (Inst); Genentech (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis/Pfizer (Inst); Regeneron (Inst)
 
Daanish Hoda
Stock and Other Ownership Interests - Aprea Therapeutics; Forty Seven
 
Edward J. Licitra
No Relationships to Disclose
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Nikolaus S. Trede
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Lei Wang
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jerill Thorpe
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Fate Therapeutics; Iovance Biotherapeutics
 
Leo I. Gordon
Consulting or Advisory Role - Bayer; Gilead Sciences; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Zylem